Intuitive Surgical (NASDAQ: ISRG) posted non-GAAP EPS of $3.00 in Q3, beating estimates by $0.35 on revenue of $3.05 billion, which cleared consensus by $148 million. The headline numbers were strong. The more interesting story sits underneath.
The da Vinci 5 platform drove 315 of the 546 systems placed in the quarter, nearly double the 240 from a year ago. That matters. DV5 systems fetch higher average selling prices and generate more instruments and accessories revenue across their lifecycle.
Revenue climbed 22% year over year to $3.05 billion. Instruments and accessories rose 18% to $1.80 billion. Systems revenue jumped 30% to $769 million. Procedure volume increased 15% globally, with da Vinci procedures up 14% and Ion procedures surging 31%. The installed base of da Vinci systems reached 12,094, up 12%. Ion's installed base hit 1,152, up 21%. This is not a one-off quarter. The installed base growth, and particularly the mix shift toward DV5, builds a recurring revenue stream that should run through 2027.
GAAP net income was $523 million, or $1.49 per diluted share, down from $704 million a year ago. The decline came entirely from a $450 million pre-tax charge to settle the da Vinci antitrust class action litigation. Strip that out, and non-GAAP net income rose to $1.05 billion from $867 million. A $22 million benefit from tariff refunds under IEEPA added $0.06 to both GAAP and non-GAAP EPS.
The buyback was aggressive. Intuitive repurchased 7.8 million shares for $2.94 billion in Q3 alone. That is a sharp acceleration from prior quarters and it ate into cash reserves. Cash, cash equivalents, and investments fell to $6.80 billion from $8.63 billion at the end of Q2. Management is clearly confident in the underlying business. The tradeoff is reduced financial flexibility while the company is pouring capital into manufacturing capacity and R&D.
Guidance for full year 2026 landed largely in line with expectations. Worldwide da Vinci procedure growth is expected at 14% to 15%, with management indicating the midpoint. Non-GAAP gross profit margin is forecast at 68.7% to 69.3%, including an estimated 0.9% drag from tariffs. Non-GAAP operating expense growth is expected at 11% to 13%. The company did not raise guidance despite the Q3 beat. That suggests caution about the macro environment and the potential for additional tariffs. The tariff refunds recognized in Q3 are unlikely to repeat, and the company noted that further tariff actions could have a material adverse impact.
Margins deserve attention. Non-GAAP gross margin came in at 69.9% in Q3, up from 68.0% a year ago and essentially flat sequentially from 70.0% in Q2. Higher revenue and operating leverage drove the improvement. The guidance range implies some compression in Q4. The tariff drag is real, and the company's manufacturing presence in Mexico and Germany leaves it exposed to trade policy shifts. The 0.9% tariff impact baked into guidance is a floor.
Procedure volume growth remains sturdy. The DV5 upgrade cycle is accelerating. The installed base is growing at 12%, and each new system spins off recurring instrument revenue. The buyback is a vote of confidence. The risk is that the cash burn rate is unsustainable at current levels, and the company may need to throttle repurchases to maintain its investment grade profile. For now, the operating momentum is strong enough to look through the litigation charge and tariff uncertainty.